Product Description
an investigational acetyl-CoA carboxylase inhibitor (ACCi) (Sourced from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline)
Mechanisms of Action: ACC Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Hepatitis|Hepatitis, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Canada, China, India, Japan, Korea, Poland, Puerto Rico, Slovakia, Taiwan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
C3711005 | P2 |
Completed |
Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2022-03-31 |
|
CTR20210412 | P2 |
Not yet recruiting |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
None |